Insmed to host conference call Conference call to discuss results from U.S. phase 2 clinical trial for treatment resistant nontuberculous mycobacteria lung infections will be held on March 26 at 8 am. Webcast Link
Insmed personnel strong, says Piper Jaffray After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.